Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.41 |
| ▸ | SRC | P12931 | 12/20 | 0.41 |
| ▸ | LYN | P07948 | 12/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15006322 | 0.93 | BTK (0.44) | BTKSRCLYNALDH1A1 | |
| SCHEMBL14999841 | 0.91 | BTK (0.41) | BTKSRCLYNALDH1A1 | |
| SCHEMBL5062666 | 0.90 | FGFR1 (0.38) | BTKSRCLYNALDH1A1 | |
| SCHEMBL14999870 | 0.88 | FGFR4 (0.37) | BTKSRCLYNALDH1A1 | |
| SCHEMBL4566697 | 0.83 | FGFR1 (0.39) | BTKSRCLYNALDH1A1 | |
| SCHEMBL14999862 | 0.83 | BTK (0.49) | BTKSRCLYNKRASRAF1 | |
| SCHEMBL5057701 | 0.81 | FGFR1 (0.43) | BTKSRCALDH1A1 | |
| SCHEMBL15289530 | 0.80 | ALDH1A1 (0.41) | SRCKRASRAF1BRAFKDR | |
| SCHEMBL14999857 | 0.80 | KIT (0.43) | BTKSRCLYNKRASRAF1 | |
| SCHEMBL14999895 | 0.80 | KRAS (0.46) | BTKSRCLYNKRASRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48731-E1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| US-RE48731-E1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3722296-A2 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3722296-A2 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3366293-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3366293-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2858646-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2858646-B1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC | 2015-11-12 | — | — | US | disclosed |
| US-8940756-B2 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC | 2015-01-27 | — | — | US | disclosed |
| US-8940756-B2 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC | 2015-01-27 | — | — | US | disclosed |
| US-8940756-B2 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC | 2015-01-27 | — | — | US | disclosed |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8461179-B1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461179-B1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461179-B1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320759-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NME1, DCK, NME2 | BTK 1971/4885SRC 715/4885LYN 1065/4885 |
| US-20140088075-A1 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NME1, DCK, NME2 | BTK 1971/4885SRC 715/4885LYN 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.